Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabinoids for Behavioral Problems in ASD
NCT02956226Phase 2Completed
- Sponsor
- Shaare Zedek Medical Center
- Start
- Jan 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol and dronabinol in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Shaare Zedek Medical Center. Primary endpoints: Home Situations Questionnaire-Autism Spectrum Disorder at 3 months and Clinical Global Impression-Improvement at 3 months. Started Jan 2017; status: completed.
02
Drugs
cannabidioldronabinol
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02956226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956226.